Adept4 (AD4 LN) Satisfactory progress against key objectives for 2018 | Ergomed (ERGO LN) TU disappoints but medium-term outlook bright | Redde (REDD LN) In line FY update, no change to forecasts | Small-cap quantitative research Momentum screen refresh + 7 highlighted stocks | Summit Therapeutics (SUMM LN) PhaseOut DMD misses endpoint: ezutromid development terminated
28 Jun 2018
Morning Song
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Song
CloudCoCo Group Plc (CLCO:LON), 0.8 | Redde Northgate PLC (21W:FRA), 0 | Summit Therapeutics Inc (SMMT:NAS), 0
- Published:
28 Jun 2018 -
Author:
N+1 Singer Team -
Pages:
13
Adept4 (AD4 LN) Satisfactory progress against key objectives for 2018 | Ergomed (ERGO LN) TU disappoints but medium-term outlook bright | Redde (REDD LN) In line FY update, no change to forecasts | Small-cap quantitative research Momentum screen refresh + 7 highlighted stocks | Summit Therapeutics (SUMM LN) PhaseOut DMD misses endpoint: ezutromid development terminated